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Abstract
The KZN strain family of Mycobacterium tuberculosis is a highly virulent strain endemic to the KwaZulu-Natal region of South
Africa, which has recently experienced an outbreak of extensively-drug resistant tuberculosis. To investigate the causes and
evolution of drug-resistance, we determined the DNA sequences of several clinical isolates - one drug-susceptible, one
multi-drug resistant, and nine extensively drug-resistant - using whole-genome sequencing. Analysis of polymorphisms
among the strains is consistent with the drug-susceptibility profiles, in that well-known mutations are observed that are
correlated with resistance to isoniazid, rifampicin, kanamycin, ofloxacin, ethambutol, and pyrazinamide. However, the
mutations responsible for rifampicin resistance in rpoB and pyrazinamide in pncA are in different nucleotide positions in the
multi-drug-resistant and extensively drug-resistant strains, clearly showing that they acquired these mutations
independently, and that the XDR strain could not have evolved directly from the MDR strain (though it could have
arisen from another similar MDR strain). Sequencing of eight additional XDR strains from other areas of KwaZulu-Natal
shows that they have identical drug resistant mutations to the first one sequenced, including the same polymorphisms at
sites associated with drug resistance, supporting the theory that this represents a case of clonal expansion.
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Introduction
Outbreaks of extensively drug-resistant (XDR) tuberculosis have
become an increasing threat in certain regions around the world
[1]. Though initially defined as resistance to isoniazid (INH),
rifampicin (RIF), and 3 or more of the 6 classes of second-line
drugs, the current definition of XDR-TB was changed by the
WHO in 2006 to be: resistance to 1) INH, 2) RIF, 3) any of the
fluoroquinolines, and 4) at least one of the second-line injectables
(such as kanamycin, amikacin, or capreomycin). One of the most
notable outbreaks was in the KwaZulu-Natal (KZN) region
between 2005–2007 on the eastern seaboard of South Africa,
where there is a high incidence (80%) of co-infection with HIV [2].
Among patients with TB that tested culture-positive in this region,
39% had MDR-TB, 6% had XDR-TB, and 44 out of 44 tested
were HIV+. The outbreak of XDR in KwaZulu-Natal was initially
reported in 2006. However, a retrospective analysis of M.
tuberculosis isolates indicates that the first known cases of XDR-
TB appeared in 2001, at the time a standard treatment regimen
for MDR-TB was introduced which includes fluoroquinolones and
kanamycin [3]. The XDR strain appears to be unique to this
region, with a distinct genotype (by spoligotyping) referred to as
F15/LAM4/KZN [3]. MIRU and RFLP analysis of several
hundred other cases of XDR-TB found in other provinces in
South Africa show a broad range of different genotypes, including
variants of M. tb strain families Haarlem, EAI, LAM, and X [4].
The XDR-TB strain is considered to be at least as virulent as
any other TB strain, with high mortality rates observed. For
example, in the 2006 KwaZulu-Natal epidemic, 52 out of 53
patients with XDR-TB and HIV co-infection died, with a mean
time from specimen collection to death of 16 days [2]. In a study of
174 patients a treatment clinic specializing in respiratory diseases
in Denver, Colorado, the relative risk of death among patients
with XDR-TB was found to be 7.9 times higher than for patients
with MDR-TB, even with extensive treatment [5]. Similarly, in a
study of HIV-negative patients in Italy and Germany, patients
with XDR-TB were found to have a 5-fold higher risk of death
and longer hospitalization/treatment times [6]. In Uzbekistan, 9 of
18 patients with XDR-TB died following treatment efforts [7].
However, interpretation of these results can be confounded by
other factors such as untimely diagnosis and improper manage-
ment. Quantitative differences in relative fitness of the XDR strain
in the KZN region of South Africa (in spite of the burden of
carrying mutations conferring drug resistance), as well as
differences in transmissibility of this strain, remain unclear [8].
There are several hypotheses about the origin and nature of
XDR strains. With bacterial infections other than TB, the
appearance of drug-resistant strains is associated with chemother-
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apeutic usage patterns. This results from selection of naturally-
occurring variants resistant to the drugs used. It has been
suggested that occurrence and spread of XDR-TB in the KZN
region could be related to the use of standard treatment regimens
and the lack of susceptibility testing to determine appropriate
chemotherapy regimens [3]. Since the F15/LAM4/KZN family of
strains was already present throughout the province of KwaZulu-
Natal in the susceptible as well as the MDR form in 1994 [3], the
emergence of the XDR form of the strain can be explained in two
ways. There could be clonal spread of one strain from one source
throughout the province. This appears to have been the case for
the outbreak of multi-drug resistant TB in New York City in the
early 1990’s, which was later shown to be a unique variant of the
W-Beijing strain family [9]. Similarly, in the study in Uzbekistan,
13 of 18 patients with XDR-TB were infected with the same strain
(based on DNA fingerprint), supporting the idea that a particular
drug-resistant strain can achieve prevalence within a population
through clonal expansion [7]. Alternatively, multiple mutational
events could have taken place independently in different strains in
the province, resulting in a pool of pre-existing mutants that are
selected through chemotherapy [10]. Until recently, it has been
assumed that drug-resistant mutants have lower fitness and tend
not to spread because they will be out-competed by wild-type
strains [11]. However, theoretical simulations show that even
presumably ‘‘less-fit’’ infectious organisms can thrive within an
isolated host population under the right circumstances, particu-
larly when the drug-susceptible wild-type population is suppressed
via a community-based drug-treatment program [12]. Important-
ly, while the clonal expansion hypothesis for the XDR outbreak in
the KZN region of South Africa has been suggested in the
literature [3], no experimental evidence has been presented to date
to confirm this hypothesis.
The genomes of a wild-type KZN strain (KZN 4207), an MDR
strain (KZN 1435), and an XDR strain have been partially
sequenced at the Broad Institute (Cambridge, MA) and have been
available for download since 2007 (www.broad.mit.edu/annotation/
genome/mycobacterium_tuberculosis_spp). Partial analysis by Bishai’s
group has identified several known mutations in genes related to drug-
resistance [8]. However, a thorough analysis of the differences among
the strains is not possible because the MDR and XDR genome
sequences are significantly incomplete. For example, they each contain
,5000 ambiguous nucleotides ‘N’ (5,708 in KZN-1435 and 5,657 in
KZN-605) and have numerous 1 bp insertions/deletions in multiple
genes (e.g. dnaB, secA, tuf). Another indication of incompleteness is that
the Broad Institute’s sequence for the MDR strain (KZN-1435) has
150 short indels (,100 bp) and 46 large indels (.100 bp) relative to
the wild-type strain, and the XDR sequence has 162 short indels and
37 large indels. The sequences of all three strains, including the wild-
type, show a large-scale inversion of ,2.5 Mb (spanning coordinates
,1 Mb to ,3.5 Mb, relative to the origin of replication). In order to
validate the sequence of the wild-type strain and to determine the
complete MDR and XDR sequences, we independently sequenced
three KZN strains (one wild type, one MDR, and one XDR) using
whole-genome sequencing. Although the wild-type strain was the same
as previously sequenced (KZN 4207), we utilized the distantly-related
F11 South African strain as a reference to avoid bias, completely
independently from the Broad Institute’s sequence. The two sequences
are very similar, except that we do not find evidence for the 2.5 Mb
inversion. However, our MDR and XDR genomes sequences are
more complete, in contrast with those available from the Broad
Institute, allowing a more accurate identification of polymorphisms
relevant to drug resistance.
Results
Genome Sequences of Drug-Susceptible, MDR, and XDR
Strains from KZN
The three strains from KwaZulu-Natal, designated KZN-
V4207 (drug-susceptible), KZN-V2475 (MDR), and KZN-R506
(XDR), were obtained from patients diagnosed with pulmonary
tuberculosis in 1994, 1995 and 2006 respectively (see Table 1). All
patients lived in Durban, the largest city in the Kwa-Zulu-Natal
region of South Africa. The first two patients were enrolled in the
Mycobacterium vaccae vaccine trial [13], while the last patient is part
of an on-ongoing study on hospital transmission of MTB. None of
the patients was on anti-TB treatment at the time of sputum
collection. Strain KZN-V2475 is phenotypically resistant to the
first-line drugs isoniazid and rifampicin, as well as streptomycin,
while strain KZN-R506 had been found to be resistant to
isoniazid, rifampicin, streptomycin, kanamycin, and ofloxacin.
Table 1. Epidemiological data on strains sequenced in this study.
strain id type drug resistancea year of collection geographic location clinicb age gender HIV status clincal outcome
V4207 DS none 1995 n.a. KGV 34 yr female positive healthy
V2475 MDR IR 1994 n.a. KGV 24 yr female positive died
R506 XDR IRSOK 2006 Phoenix, DBN KGV 34 yr female n.a. n.a.
n.a.
R257 XDR IROK 2005 Tugela Ferry KGV 38 yr female positive n.a.
R262 XDR IRESOK 2005 Durban KEH 38 yr female positive n.a.
R299 XDR IRSOK 2005 Pomeroy KGV 33 yr female positive n.a.
R376 XDR IROK 2005 Greytown KGV 28 yr female positive n.a.
R503 XDR IRSOK 2005 Pietermarizburg KGV 31 yr female positive n.a.
TF274 XDR IRSEOK 2005 n.a. Mosvold n.a. n.a. n.a. n.a.
TF275 XDR IRSEOK 2005 Tugela Ferry COSH n.a. n.a. n.a. n.a.
TF490 XDR IRSOK 2005 n.a./Mosvold Mosvold n.a. n.a. n.a. n.a.
n.a. = not available, DS = drug susceptible.
aI = isoniazid, R = rifampicin, S = streptomycin, O = ofloxacin, K = kanamycin, E = ethambutol.
bKGV=King George V Hospital, Syndenham; KEH= King Edward VIII Hospital, Congella; COSH=Church of Scotland Hospital, Tugela Ferry.
doi:10.1371/journal.pone.0007778.t001
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The genomes of the three KZN strains were sequenced to
.99% completion using the Illumina Genome Analyzer in so-
called paired-end mode with greater than 134-fold depth of
coverage. The 36-bp reads were assembled by mapping them onto
the reference sequence for F11, a strain from the Western Cape of
South Africa [14], and applying local contig-building to resolve
apparent differences into SNPs (single nucleotide polymorphisms)
and indels (insertions/deletions). The resulting (circular) genome
of KZN-V4207 has 4,397,375 nucleotides and has an overall
depth of coverage (average redundancy) of 134.3-fold, with a
standard deviation of 41.4 (excluding the top 5% of most-highly
covered sites as outliers due to redundancy). There are only 14,225
sites with a coverage of zero, mostly associated with GC-rich
regions where sequencing was inefficient (9,267 sites with zero-
coverage were in PGRS genes, though this represents less than
10% of the coding region spanned by this family). Analysis of the
direct-repeats (DR) region indicates that KZN-V4207 has a
spoligotype pattern that is missing spacers 21–24, 33–36, and 40.
This is consistent with the F15/LAM4/KZN spoligotype reported
by Pillay and Sturm [2].
A comparison of our sequence of KZN-V4207 to H37Rv shows
that at least 973 isolated SNPs are observed (not counting those
associated with indels), along with 71 small insertion/deletions
(1–9 bp) and 71 medium-sized insertion/deletions (10–1000 bp).
In addition, there were 28 large-scale polymorphisms (insertions or
deletions .1000 bp). Many of these (15) were associated with
transpositions of the IS6110 insertion elements (1355 bp repetitive
elements with flanking direct repeats that contain a transposase
[15]). One copy of IS1547 was also lost. The largest insertion is a
5 kb insertion in Rv2024c, which corresponds to a region
containing a hypothetical protein and a cation efflux pump in
other mycobacterial strains like H37Ra and F11 that had been lost
in H37Rv. The largest deletion is a 9 kb region representing part
of Rv1572c through Rv1587c (all annotated as hypothetical
proteins); this region is also deleted in F11. Table S1 lists the
locations and identities of the large-scale polymorphisms observed.
When compared to the F11 genome, the KZN-V4207 sequence is
observed to have fewer differences (530 SNPs, 35 small indels, and
22 large-scale indels; described in Supplemental Material),
implying that they are more closely related.
The genome for KZN-V4207 has been independently
sequenced at the Broad Institute (no data on depth of coverage
was available). When our sequence is compared to the Broad’s
sequence, the sequences are identical in most functionally-
significant regions. The differences are mostly associated with
low-coverage regions or repetitive sequences. There are only 3
sites where the two sequences clearly disagree: a 1 bp insertion
(933401 +t) near the end of an IS6110 transposon sequence, a
1 bp deletion (1277912 –g) in a 13E12 repeat, and a 1 bp deletion
(1533528 –c) in PPE19. At all these sites, coverage by our reads
was significantly higher using our corrected version of the genome
sequence. The Broad Institute’s KZN-V4207 sequence has a
large-scale inversion of ,2.5 Mb; however, this inversion was not
observed in our sequencing data.
Many of the large-scale insertion/deletions among mycobacte-
rial genomes involve IS6110 insertion sequences, which are an
active family of transposons [15]. There are 16 copies of IS6110 in
the H37Rv genome (see Figure 1). In F11, there are 17 copies;
however many of these differ from H37Rv and represent new
insertion sites. Only 5 IS6110 sites are shared in common between
H37Rv and F11, 11 were excised from H37Rv, and 12 are new
insertion sites in F11. By comparison, KZN-V4207 has 12 copies
of IS6110. Of these 5 are the same as in F11, 6 are new insertion
sites, and one (at 2.36 M) is the same as in H37Rv but is deleted in
F11. Only 2 insertion sites are shared across all 3 strains (the one in
the DR region, and IS6110–14 near Rv3324c/moaC). As
previously reported, the insertion sites are accompanied by a local
3–4 bp tandem duplication that do not demonstrate any obvious
sequence pattern [15]. As can be seen in Table S1, some insertions
occur in non-coding regions and others occur in open-reading
frames (Rv2492, Rv2775, and Rv3113 – all hypothetical genes),
though none appear to occur in previously identified putative
‘‘hot-spots’’ [16] including the ipl loci [17]. There are two cases
where an IS6110 sequence appears to have been deleted from one
strain and re-inserted nearby in the opposite direction in KZN:
one which is shared between H37Rv and KZN-V4207 (at
Figure 1. Locations of the IS-6110 insertion sequences in H37Rv, F11, and KZN-V4207. The dashed lines indicate insertion sites that have
been preserved between strains. The sites are only drawn approximately to scale.
doi:10.1371/journal.pone.0007778.g001
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2.36 Mb, corresponding to IS6110-5 in H37Rv), the other being
the IS6110 at 2.62 Mb that is shared with F11.
The sequences for the MDR and XDR strains were determined
in a similar fashion with the Illumina GAII (in paired-end mode),
except our KZN-V4207 sequence was used as the reference
sequence for mapping reads. The depth of coverage was 174.7-
fold and 188.3-fold, respectively. Overall, the MDR and XDR
strains were found to be very similar to KZN-V4207; all three
have exactly the same spoligotype. Only 67 polymorphisms were
found in the MDR strain KZN-V2475, and 83 polymorphisms
were localized to the XDR strain KZN-R506. Of these
polymorphisms, 43 were shared between the two drug-resistant
strains, relative to the drug-susceptible KZN-V4207, while 24 are
unique to KZN-V2475 (MDR) and 40 are unique to KZN-R506
(XDR) (see Table 2). For cases where the MDR and XDR strains
share a different relative to the wild-type, comparison of the two
nucleotides to reference sequences for genomes of drug-susceptible
strains (H37Rv, CDC1551, M. tb haarlem, and M. bovis) was used
to determine which was the putative ancestral (non-mutated) form.
This analysis shows that 29 of the 43 shared differences are unique
to the two drug-resistant KZN strains, and 14 differences are
unique to the KZN wild-type (where the nucleotide in the MDR
and XDR strains matches the one observed in drug-susceptible
strains) (see Table 2). The two drug-resistant strains also shared a
130 bp deletion in gidB (glucose-inhibited division protein B),
relative to KZN-V4207. Tables 3, 4, 5, 6 show a selected list of
mutations observed (the complete list of polymorphisms is
presented in Table S2 in the Supplemental Material). The
KZN-R506 (XDR) strain also has a cluster of 8 SNPs within a
span of 33 base positions in pks12, a 4151-amino acid polyketide
synthase which is involved in mycoketide biosynthesis [18].
Separately, the KZN-V2475 (MDR) strain has a cluster of 6
SNPs within 9 base positions in PPE40. The significance of these
two clusters is unclear.
Analysis of Mutations Related to Drug Resistance
Despite the fact that the two drug-resistant strains are clearly
distinct (with 24 polymorphisms unique to the MDR strain and 40
unique to the XDR strain, as discussed above), the pattern of
mutations in each is consistent with the clinical drug-susceptibility
profiles of these strains. Recall that, while both strains KZN-
V2475 and KZN-R506 are resistant to INH, RIF, and STR,
KZN-R506 alone is also resistant to kanamycin and ofloxacin.
Consistent with this, only the XDR strain KZN-R506 shows a
mutation in rrs, the 16S rRNA, at position 1400, which explains
the kanamycin resistance [19], and only the XDR strain has the
A90V mutation in gyrA responsible for resistance to fluoroquin-
olones [20]. The mutation at 1400 in rrs is the most commonly
observed mutation associated with kanamycin resistance, found in
60% of RIF-resistant clinical isolates [19]. The A90V in gyrA is the
second-most frequently observed mutation conferring FQ resis-
tance, found in 24% of FQ-resistant clinical isolates [21].
With respect to isoniazid (INH) resistance, both strains have the
mutation of S315T in katG, the catalase/peroxidase that activates
the pro-drug isoniazid [22]. This is the most frequently observed
mutation associated with isoniazid resistance [23]. It confers high-
level resistance at .5 mg/ml, compared to an MIC of 0.05 mg/ml
for wild-type H37Rv [24]. Unexpectedly, both strains also have a
mutation at -8 upstream of mabA, at the start of the operon
containing the enyol-acyl-ACP reductase inhA (the target of the
INH-NADH adduct). While mutations in this region have been
reported to cause INH-resistance [23], presumably by up-
regulation of expression, it is unclear why both drug-resistant
strains would have this mutation, given that it is redundant with
Table 2. Summary of polymorphisms observed in KZN strains.
polymorphism type H37Rv KZN-V4207 KZN-V2475 KZN-R506 # of sites
unique to wild-type A B A A 14
unique to MDR A A B A 24
unique to XDR A A A B 40
shared by MDR and XDR A A B B 29
‘A’ and ‘B’ indicate nucleotide identity patterns. ‘A’ represents the nucleotide in the H37Rv reference genome. An ‘A’ in the column of a KZN strain means that it matches
the nucleotides at the corresponding sites in H37Rv. If a KZN strain has a ‘B’, this means it has a different nucleotide than H37Rv at those positions.
doi:10.1371/journal.pone.0007778.t002
Table 3. Polymorphisms in the MDR strain, KZN-V2475, relative to the drug-susceptible wild-type, KZN-4207.
gene mutation function known resistance effect
Rv0667 (rpoB) D435Y RNA-polymerase beta-subunit rifampicin
Rv0678 M139I transcriptional regulator
Rv0897c T271M possible oxidoreductase
Rv1940 (ribA1) G251S GTP cyclohydrolase (riboflavin biosynthesis)
Rv2043c (pncA) G132A pyrazinamidase (nicotinamide biosynthesis) pyrazinamide
Rv2545 P19L hypothetical
non-coding region t2969973c 2150 bp upstream from Rv2645
Rv3921c I256V putative membrane translocase yidC
This table excludes synonymous mutations in coding regions, and mutations in PPE/PGRS genes or repetitive sequences. Mutations in coding regions are numbered as
amino acids substitution (upper case). Numbering of base substitutions (lower case) in non-coding regions is given relative to the H37Rv genome.
doi:10.1371/journal.pone.0007778.t003
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Table 4. Polymorphisms in the XDR strain, KZN-R506, relative to the drug-susceptible wild-type, KZN-4207.
gene mutation function known resistance effect
Rv0006 (gyrA) A90V DNA gyrase fluoroquinolones
Rv0119 (fadD7) I200V fatty-acid CoA synthetase
non-coding region c664929a 2111 bp upstream of Rv0571c
Rv0667 (rpoB) D435G RNA-polymerase beta-subunit rifampicin
Rv0667 (rpoB) L452P RNA-polymerase beta-subunit
Rv0667 (rpoB) I1106T RNA-polymerase beta-subunit
Rv0849 T403I MFS drug transporter
non-coding region c1272321a 2102 bp upstream of Rv1145(mmpL13a)
Rvnr01 (rrs) a1400g 16S ribosomal RNA kanamycin
Rv2000 L275P hypothetical protein
Rv2043c (pncA) +g in A152 pyrazinamidase (nicotinamide biosynthesis) pyrazinamide
Rv2692 (ceoC) S82R TRK potassium transporter
Rv3471c D64E hypothetical protein
non-coding region t4056430c 255 bp upstream of Rv3616c
Rv3806c V188A PRPP:decaprenyl-phosphate phosphoribosyltransferase
This table excludes synonymous mutations in coding regions, and mutations in PPE/PGRS genes or repetitive sequences. Mutations in coding regions are numbered as
amino acids substitution (upper case). Numbering of base substitutions (lower case) in non-coding regions is given relative to the H37Rv genome.
doi:10.1371/journal.pone.0007778.t004
Table 5. Polymorphisms unique to the drug-susceptible wild-type, KZN-4207.
gene mutation function known resistance effect
Rv0057 L28M hypothetical protein
Rv0232 +a 1 bp ins. in S127 transcription factor
non-coding region c713955t 2247 bp upstream of Rv0621
Rv0691c P61S transcriptional regulator
Rv1459c P318S membrane protein
This table excludes synonymous mutations in coding regions, and mutations in PPE/PGRS genes or repetitive sequences. Mutations in coding regions are numbered as
amino acids substitution (upper case). Numbering of base substitutions (lower case) in non-coding regions is given relative to the H37Rv genome.
doi:10.1371/journal.pone.0007778.t005
Table 6. Polymorphisms shared between the drug-resistant strains KZN-V2475 and KZN-R506, relative to KZN-V4207, and not
found in drug-susceptible strains.
gene mutation function known resistance effect
Rv0103c (ctpB) G23S cation-transporter ATPase
non-coding region t1096633g 2183 bp upstream of Rv0981(mprA)
non-coding region t1673432a 28 bp upstream of operon containing inhA isoniazid
Rv1908c (katG) S315T catalase/peroxidase isoniazid
Rv3926 (drrA) R262G membrane transporter
Rv3795 (embB) M306V membrane protein, arabinosyltransferase ethambutol
non-coding region t4327484c 211 upstream of ethA ethionamide
Rv3919c (gidB) 2130 bp del, (L50–P93) 16S rRNA methyltransferase streptomycin
This table excludes synonymous mutations in coding regions, and mutations in PPE/PGRS genes or repetitive sequences. Mutations in coding regions are numbered as
amino acids substitution (upper case). Numbering of base substitutions (lower case) in non-coding regions is given relative to the H37Rv genome.
doi:10.1371/journal.pone.0007778.t006
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the mutation in katG. One possibility is that a mutation that causes
a lower-level of resistance was acquired first, followed by the
acquisition of a subsequent mutation that afforded a greater
degree of resistance (e.g. higher MIC), enhancing fitness/survival
as a isoniazid became more widely deployed in a region.
Mutations at the nearby -15 position upstream of the inhA operon
only increase the MIC several fold. However, simultaneous
mutations in katG and the promoter region of inhA have previously
been observed. For example, in a study of 41 clinical isolates with
ETH/INH co-resistance [25], 26 were found to have the c-15t
inhA promoter mutation, and of these, 6 also had mutations in
katG.
Resistance to rifampicin (RIF) can be explained by mutations in
rpoB (beta-subunit of RNA polymerase). The mutation of Asp 435
in rpoB, corresponding to Asp 516 in the E. coli numbering, has
been previously observed to confer RIF resistance [26]. This is in
the core 507–533 region, in which numerous mutations have been
observed to cause resistance to RIF, although mutations at other
sites in this region are more frequent (mutations specifically at Asp
435 constitute only 9% of all RIF-R cases). However, it is
interesting to note that the two KZN strains have different
mutations within the same codon, leading to different amino acid
substitutions. Strain KZN-V2475 has a G-.T substitution in
frame 1, producing D435Y, and KZN-R506 has an A-.G
substitution in frame 2, producing D435G. This suggests that the
two strains acquired rifampicin resistance independently. It is also
notable that the XDR strain, KZN-R506, contains two additional
mutations in rpoB, L452P and I1106T; the former (corresponding
to Leu 533 in E. coli) is also thought to cause RIF-resistance, while
the latter is not.
Streptomycin (STR) resistance is most likely due to a 130 bp
deletion in gidB found in both drug-resistant strains (MDR and
XDR), but not the wild-type. The classic STR-R mutations that
have been correlated with streptomycin-resistance in the 530-loop
or 915-region of rrs, the 16S ribosomal RNA, or in rpsL, the
ribosomal protein S12, were not observed in either strain.
However, mutations in these two genes explain only about 70%
cases of STR resistance in clinical isolates [27], implying that there
must be other loci that can be responsible. Recently, it was
discovered by genetic mapping and comparative sequencing that
mutations in gidB can cause low-level resistance to streptomycin in
S. coelicolor [28]. This gene had originally been annotated as a
glucose-inhibited division protein, but was later shown to be a
SAM-dependent methyltransferase that methylates G527 in the
16S ribosomal RNA [28], providing an additional hydrophobic
contact point in the binding site for streptomycin. A gidB deletion
mutant increased the MIC for streptomycin from 2 mg/ml to
15 mg/ml in E. coli, and could be complemented by the wild-type
gene [28]. Although mutations in gidB have previously been
observed in clinical isolates of M. tuberculosis [28–30], this 130 bp
deletion is distinct from every other gidB mutation previously
reported. The 130 bp gidB deletion observed in the KZN MDR
and XDR strains spans amino acids 50–93, which encompasses
the SAM-binding site (residues 67–77) [31], and causes a frame
shift for C-terminal remainder, which presumably abbrogates
function completely.
Both strains also show classic mutations in embB, pncA, and the
promoter region of ethA, which are associated with resistance to
ethambutol (EMB), pyrazinamide (PZA), and ethionamide (ETH),
though susceptibility to these drugs was not tested. The M306V
mutation in the transmembrane protein embB is one of the most
frequently observed mutations in EMB-resistant strains [32],
putatively preventing ethambutol from interfering with biosynthe-
sis of the arabinogalactan layer in the cell wall. In the case of pncA,
the two drug-resistant KZN strains showed different mutations in
pncA (a pyrazinamidase, which is thought to be involved in
nicotinamide biosynthesis). The MDR strain KZN-V2475 has a
G132A mutation, and mutations of this residue have previously
been reported to cause resistance to PZA [33]. Strain KZN-R506
has a frame-shift mutation in amino acid 152 caused by an
insertion of 1 bp, and missense mutations that cause resistance
have been observed downstream of this site (so the C-terminus of
the 186-residue gene product must be important). In addition, the
two drug-resistant strains also share a mutation at position 28
upstream of the translational start site of ethA, which is a
monooxygenase that activates thioamides such as ethionamide,
isoxyl, and thioacetazone as pro-drugs [34]. A mutation in the
upstream region could potentially confer resistance by increasing
expression. However, susceptibility of the KZN strains to these
drugs was not determined.
Whole-Genome Sequencing of Additional XDR Strains
To determine whether this pattern of drug-resistance mutations
was common to other XDR strains from KZN, we sequenced eight
additional strains fitting the XDR profile, including clinical isolates
obtained from other sites in the KZN region: TF274, R257, R503,
R262, R299, TF275, R376, and TF490 (the three ‘TF’ strains were
obtained from Tugela Ferry, approximately 60 miles north of
Durban). All strains tested resistant to isoniazid (I), rifampicin (R),
streptomycin (S), ofloxacin (O), and kanamycin (K) with the
exception of strain R257, which is streptomycin-susceptible but
resistant to the other four drugs. The sequencing on the Illumina
GAII was performed only in single-ended mode for these strains.
Reads of length 18 bp were collected for the first 5 strains, and reads
of length 36 bp were collected for the last 3 strains. Despite this, we
were able to get a mean depth of coverage of 24.0–41.4 over 99.8%
of the genome. The KZN-V4207 wild-type sequence was used as a
reference strain during sequence determination (alignment and
contig-building) to reduce the possibility of bias.
When the 8 strains are put in a multiple alignment and
examined for sites where there are confident differences (where
two or more strains have different nucleotides, coverage .10, and
homogeneity.90%), the strains appear to have nearly identical
sequences. Only 5 sites (excluding those in PGRS genes and
repetitive elements) met these criteria (in nrp, fadD7, rpsK, and two
non-coding regions, sites where the base call in one or two strains
differs from the others).
The bases in these 8 strains were specifically examined at 44
positions where polymorphisms were observed among the wild-
type, MDR, and XDR strains (KZN-V4207, KZN-V2475, and
KZN-R506, respectively) (see Table S3). The 8 strains match the
base in the XDR strain 41 out of 44 positions (excepting sites in
strains where there is near-zero coverage (,4) or significant
heterogeneity (.30%)), regardless of whether these sites harbored
MDR-specific mutations, XDR-specific mutations, or common
differences in MDR and XDR relative to wild-type. One exception
is the fadD7 site mentioned above; a second polymorphic site is in
mraW (an S-adenosyl methyl transferase), where R299 and TF275
share a ‘g’ with the XDR KZN-R506 (allowing up to 20%
heterogeneity), whereas the other 6 strains share a ‘c’ with theMDR
KZN-V2475 strain; a third site with a similar pattern is in Rv0849,
an MFS membrane transport protein. Importantly, all 8 strains
agree with the base in the XDR strain at polymorphic sites
associated with drug resistance. In particular, they all show the same
rifampicin-resistance mutation (D435G) in rpoB that distinguishes
the XDR sequence from the MDR sequence (D435Y). They also
share the same mutations as in both the MDR and XDR strains for
ofloxacin resistance (A90V in gyrA), ethambutol resistance (M306V
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in embB), isoniazid resistance (S315T in katG and the inhA promoter
mutation at t-8a upstream of mabA) and kanamycin resistance
(a1400g in rrs). The R257 strain appears to contain the 130 bp
deletion in gidB like the other strains, despite the fact that it was
reported to be streptomycin-susceptible. It is possible that the drug
susceptibility was mis-characterized, due to the low-level of
resistance that gidB mutations have been observed to confer [28].
The strain was unavailable for re-testing at lower concentrations.
Discussion
Based on the sequences of these KZN strains, it appears that
multi-drug resistance results from a combination of previously-
observed mutations, each responsible for resistance to a different
drug through classic mechanisms/targets. This suggests that there is
no common underlying cause of drug-resistance to multiple drugs,
such as broad-specificity drug efflux pump getting over-expressed,
or a mutation in a gene that changes the permeability of the
mycobacterial cell wall [26]. The MDR and XDR strains contain
typical mutations in gyrA, rpoB, rrs, katG, and the promoter of inhA
that explain resistance to fluroquinalones, rifampicin, kanamycin,
and isoniazid. Although susceptibilities to ethambutol and pyrazin-
amide were not determined clinically, mutations in embB and pncA
were observed as well. The fact that the MDR and XDR strains
have different mutations in rpoB and pncA suggests that they arose
separately, and that these mutations were acquired independently
after divergence. This observation argues against the hypothesis that
the XDR strain might have evolved directly from the MDR strain
(though it could have arisen from another similar MDR strain).
While resistance to streptomycin is usually associated with
mutations in rpsL or rrs, the KZN MDR and XDR strains showed
a rare 130 bp deletion in gidB. Although recent studies have begun
to show that mutations can cause low-level resistance to
streptomycin, through abbrogation of ribosomal methylation, this
mutation is unique and has never been reported before.
The observation that the eight additional extensively drug-
resistant strains isolated from the KwaZulu-Natal region in South
Africa all appear to be nearly identical to KZN-R506 strongly
suggests that the epidemic of drug-resistant tuberculosis in KwaZulu-
Natal represents a clonal expansion of the same strain. That these
drug-resistant strains can thrive and attain high-frequency in the
population despite the heavy burden of carrying so many drug-
resistance mutations could be potentially due to 1) lower fitness cost
than typically assumed, 2) offset of fitness cost by increased virulence
due to some other as yet unidentified mutation(s), or 3) side-effects of
drug treatment practices in the region that leads to the suppression of
the wild-type drug-susceptible strain locally and selection for the
drug-resistant strain(s). Another possibility is that spread of these
strains could be associated with diminished immunity in the host,
since most of the patients from which samples were obtained were
HIV-positive. Further analysis and comparison of the genome
sequences we have reported could lead to a better understanding of
the nature of the virulence of this strain.
Methods
Approval by an Institutional Review Board was not required for
this study, as no patient-specific data was reported. Nor was
patient consent required to publish genome sequences of bacterial
samples.
Drug Susceptibility Testing
The susceptibility of the clinical isolates was tested on solid media
using standard protocols [3] for drugs at the following concentra-
tions: isoniazid, 1 mg/L; rifampicin, 1 mg/L; ethambutol, 7.5 mg/
L; streptomycin, 2 mg/L; ofloxacin, 2 mg/L; kanamycin, 5 mg/L.
DNA Preparation and Sequencing Reaction
Sequencing of the genomes of three KZN strains, KZN-V4207,
KNZ-V2475, and KZN-R506, was carried out on the Illumina
Genome Analyzer II (Illumina). In this study, Illumina Paired-End
sequencing method (PE) was used. The cetyltrimethylammonium
bromide (CTAB)-lysozyme method was used for extraction and
purification of genomic DNA [35]. DNA samples were prepared
for the GAII as described on the sample preparation protocol
(Illumina). 2–3 mg of genomic DNA was initially used for sample
preparation. Genomic DNA was sheared by a nebulizer to
generate DNA fragments for the Illumina Paired-End Sequencing
method. The specific oligonucleotides (Illumina adapters) designed
for PE sequencing were ligated to both ends of DNA fragments
with the TA cloning method. Adapter-ligated DNA fragments of
length 350–400 bp were isolated from a 2% agarose gel (Certified
low-range Ultra Agarose, BIO-RAD) by using QIAquick Gel
Extraction Kit (QIAGEN). Then the fragments were amplified by
PCR reaction to generate the DNA library (15–30 ng/ml). The
median size of the library was estimated by examining the 2%
agarose gel image. The molarity of the DNA library was estimated
as described on the sample preparation protocol (Illumina): MW of
the library = S (Median size of the library) x 650. The DNA
libraries (5 pM) including wX control (bacteriophage DNA) were
loaded on the flow cell for the cluster generation and sequencing.
72 cycles of images were collected, representing pairs of 36-bp
reads. The images were analyzed using version 0.3 of the
GAPipeline software supplied by Illumina, producing files with
,30 million of pairs of 36 bp reads for each genome (28.0 M
reads for KZN-V4207, 27.1 M for KZN-V2475 and 31.2 M for
KZN-R506).
Sequence Determination and Bioinformatics
The reads were analyzed by comparative genome assembly to
determine the complete sequence of each genome using custom
software developed in our lab. The reads were first mapped
against the reference sequence for the genome of the F11 South
African strain. The mapping was accomplished by identifying the
position(s) in the genome that each fragment (including its reverse
complements) matches with no gaps and at most 2 mismatches.
Initially the reads in each pair were treated as independent;
subsequently, mapped locations of reads for which the paired-end
did not match within 300 bp were discarded. The mapped reads
were used to assemble a list of the nucleotides observed at each
position within the reference genome contributed by all the reads
that overlapped it. Base calls were made by a maximum likelihood
calculation, computed as the product of the probabilities for each
base at each position using uncertainties estimated during image
analysis. Sites where apparent differences were observed were
subjected to local contig-building (described in more detail in
Supplemental Methods in Supporting Online Material S1), in
order to determine whether the difference was due to a nucleotide
substitution or a small insertion or deletion. Larger-scale deletions
were identified by analyzing paired-end data for reads whose
paired-end maps an unusually long distance away (i.e. .300 bp,
compared to average read length of ,200). Large-scale insertions
were determined by identifying reads not mapping into the F11
genome that significantly cover regions in other mycobacterial
genomes.
For each genome, a list of contig-verified differences is prepared
and used to modify the reference genome to produce an
intermediate (‘edited’) genome. Then the process is repeated by
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re-mapping the reads against the edited genome, and re-calling
bases at each position. For any sites that still had 0 coverage, the
sequence from the reference strain was used. This included most of
the PGRS genes, which have exceptionally-high GC-content (80–
90%). In addition, any putative SNPs in low-coverage sites where
the majority base differed from the reference genome but the
majority consisted of only 1 or 2 bases were rejected due to lack of
sufficient data, and replaced with the base in the reference
genome. Information on each individual site is available as a
supplement to the genome sequence itself (using an expanded
sequence file format that indicates the called nucleotide, coverage,
quality, and other information for each position).
Virtual spoligotyping was performed by aligning (without gaps)
all the reads obtained for each KZN strain against each of the 43
spacer sequences (26-bp oligos) from the direct repeats (DR)
regions [36]. The number of matching reads for each spacer was
counted, considering both forward and reverse-complement
sequences, and accepting up to 1 nucleotide mismatch. Spacers
with 0 matches were interpreted as missing.
Whole-genome alignments of the KZN sequences to other
mycobacterial strains were generated using MUMMER version
3.20 [37].
This Whole Genome Shotgun project has been deposited at
DDBJ/EMBL/GenBank under the project accession numbers
ACVS00000000 (KZN 4207), ACVT00000000 (KZN V2475),
and ACVU00000000 (KZN R506). The full-length genome
sequences in FASTA format are provided in the Supplementary
Material, along with the inferred annotation (table of protein
coding regions) based on F11 (Tables S4, S5, S6, S7, S8, S9).
Supporting Information
Table S1 Large-scale polymorphisms between KZN-V4207 and
H37Rv. Sequence positions are given relative to H37Rv.
Found at: doi:10.1371/journal.pone.0007778.s001 (0.03 MB
DOC)
Table S2 A complete list of the SNPs found among KZN-V4207
(wt), KZN-V2475 (MDR), and KZN-R506 (XDR). Also shown
are bases at the corresponding sites for H37Rv and F11. These
positions were selected as those sites at which either the MDR or
XDR strain differed from the wild-type. The depth of coverage
and purity (percentage of bases corresponding to the majority) are
also shown. Information on the amino acid mutation and known
relationships to drug resistance are shown. The mutations are
grouped into those that are MDR-specific, XDR-specific, or found
in the wild-type strain only. NCR=non-coding region.
Found at: doi:10.1371/journal.pone.0007778.s002 (0.52 MB
DOC)
Table S3 A list of nucleotides found in XDR strains TF274,
R257, R503, R262, R299, TF275, R376, and TF490 at sites of
polymorphism among KZN-V4207 (drug susceptible), KZN-
V2475 (MDR) and KZN-R506 (XDR), excluding those in PPE
and PGRS genes, and repetitive regions. Sites with low coverage
(,4) or heterogeneity (.30%) are marked with a ‘?’. Sites where
there are differences among the 8 XDR strains are marked with a
‘*’.
Found at: doi:10.1371/journal.pone.0007778.s003 (0.03 MB
DOC)
Table S4 Full-length genome sequence of KZN 4207 in FASTA
format. Nucleotides from the reference genome F11 were used to
fill in regions with zero coverage.
Found at: doi:10.1371/journal.pone.0007778.s004 (4.46 MB
TXT)
Table S5 Inferred annotation of KZN 4207 protein coding
regions based on alignment to F11, in tab-separated ASCII
format.
Found at: doi:10.1371/journal.pone.0007778.s005 (0.38 MB
TXT)
Table S6 Full-length genome sequence of KZN V2475 in
FASTA format. Nucleotides from the reference genome F11 were
used to fill in regions with zero coverage.
Found at: doi:10.1371/journal.pone.0007778.s006 (4.46 MB
TXT)
Table S7 Inferred annotation of KZN V2475 protein coding
regions based on alignment to F11, in tab-separated ASCII
format.
Found at: doi:10.1371/journal.pone.0007778.s007 (0.39 MB
TXT)
Table S8 Full-length genome sequence of KZN R506 in
FASTA format. Nucleotides from the reference genome F11 were
used to fill in regions with zero coverage.
Found at: doi:10.1371/journal.pone.0007778.s008 (4.46 MB
TXT)
Table S9 Inferred annotation of KZN R506 protein coding
regions based on alignment to F11, in tab-separated ASCII
format.
Found at: doi:10.1371/journal.pone.0007778.s009 (0.38 MB
TXT)
Supporting Online Material S1
Found at: doi:10.1371/journal.pone.0007778.s010 (0.05 MB
DOC)
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